Loading publications…
The last 5 uploaded publications
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater, Peter R. Galle, Shahid A. Khan, Josep M. Llovet, Joong‐Won Park, Tushar Patel, Timothy M. Pawlik, Gregory J. Gores (2014). Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. Journal of Hepatology, 60(6), pp. 1268-1289, DOI: 10.1016/j.jhep.2014.01.021.
Article145 days agoBrivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul, Éveline Boucher, Masatoshi Kudo, Charissa Chang, Yoon‐Koo Kang, Éric Assenat, Ho-Yeong Lim, Valérie Boige, Philippe Mathurin, Lætitia Fartoux, Deng‐Yn Lin, Jordi Bruix, Ronnie T.P. Poon, Morris Sherman, Jean–Frédéric Blanc, Richard S. Finn, Won Young Tak, Yee Chao, Rana Ezzeddine, David Liu, Ian Walters, Joong‐Won Park (2013). Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. Journal of Clinical Oncology, 31(28), pp. 3509-3516, DOI: 10.1200/jco.2012.47.3009.
Article145 days agoMolecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
Roser Pinyol, Robert Montal, Laia Bassaganyas, Daniela Sia, Tadatoshi Takayama, Gar-Yang Chau, Vincenzo Mazzaferro, Sasan Roayaie, Han Chu Lee, Norihiro Kokudo, Zhongyang Zhang, Sara Torrecilla, Agrin Moeini, Leonardo Rodríguez‐Carunchio, Edward Gane, Chris Verslype, Adina Croitoru, Umberto Cillo, Manuel de la Mata, L. Lupo, Simone I. Strasser, Joong‐Won Park, Jordi Camps, Manel Solé, Swan N. Thung, Augusto Villanueva, Carol Peña, Gerold Meinhardt, Jordi Bruix, Josep M. Llovet (2018). Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut, 68(6), pp. 1065-1075, DOI: 10.1136/gutjnl-2018-316408.
Article145 days agoObjective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
Riccardo Lencioni, Robert Montal, Ferrán Torres, Joong‐Won Park, Thomas Decaens, Jean‐Luc Raoul, Masatoshi Kudo, Charissa Chang, José Ríos, Valérie Boige, Éric Assenat, Yoon‐Koo Kang, Ho-Yeong Lim, Ian Walters, Josep M. Llovet (2017). Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. Journal of Hepatology, 66(6), pp. 1166-1172, DOI: 10.1016/j.jhep.2017.01.012.
Article145 days agoFirst-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D. Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Joong‐Won Park, Su Pin Choo, Antoine Hollebecque, Max W. Sung, Ho-Yeong Lim, Vincenzo Mazzaferro, Joerg Trojan, Andrew X. Zhu, Jung‐Hwan Yoon, Sunil Sharma, Zhong-Zhe Lin, Stephen L. Chan, Sandrine Faivre, Lynn G. Feun, Chia-Jui Yen, Jean‐François Dufour, Daniel H. Palmer, Josep M. Llovet, Melissa Manoogian, Meera Tugnait, Nicolas Stransky, Margit Hagel, Nancy E. Kohl, Christoph Lengauer, Cori Ann Sherwin, Oleg Schmidt‐Kittler, Klaus P. Hoeflich, Hongliang Shi, Beni B. Wolf, Yoon‐Koo Kang (2019). First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery, 9(12), pp. 1696-1707, DOI: 10.1158/2159-8290.cd-19-0555.
Article145 days ago